Cystic fibrosis, an issue of clinics in chest medicine. (2016)

• Record Type: Book
• Further Information: Note: Editor Jonathan L. Koff.
• Editors: Koff, Jonnathan L
• Contents: Front Cover; Cystic Fibrosis ; Copyright ; Contributors; EDITOR; AUTHORS; Contents; Preface: Cystic Fibrosis ; Epidemiology of Cystic Fibrosis ; Genetics of Cystic Fibrosis: Clinical Implications ; Innate and Adaptive Immunity in Cystic Fibrosis ; Diagnostic Testing in Cystic Fibrosis ; Diagnosis of Adult Patients with Cystic Fibrosis ; The Microbiome in Cystic Fibrosis ; The Approach to Pseudomonas aeruginosa in Cystic Fibrosis ; Nontuberculous Mycobacterial Infections in Cystic Fibrosis ; Nutritional Issues in Cystic Fibrosis ; Gastrointestinal Disorders in Cystic Fibrosis Cystic Fibrosis Transitions of Care: Lessons Learned and Future Directions for Cystic Fibrosis Lung Transplantation for Cystic Fibrosis ; Using Cystic Fibrosis Therapies for Non-Cystic Fibrosis Bronchiectasis ; Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction in Chronic Bronchitis and Other Diseases of Mucus Clearance ; PROGRAM OBJECTIVE; TARGET AUDIENCE; LEARNING OBJECTIVES; ACCREDITATION; DISCLOSURE OF CONFLICTS OF INTEREST; UNAPPROVED/OFF-LABEL USE DISCLOSURE; TO ENROLL; METHOD OF PARTICIPATION; CME INQUIRIES/SPECIAL NEEDS; CLINICS IN CHEST MEDICINE FORTHCOMING ISSUESJune 2016; September 2016; December 2016; RECENT ISSUES; December 2015; September 2015; June 2015; Preface: Cystic Fibrosis ; Epidemiology of Cystic Fibrosis; Key points; CHANGES IN INCIDENCE AND PREVALENCE; CYSTIC FIBROSIS-RELATED CONDITIONS; DIAGNOSIS; CLASSIFICATION OF MUTANT FORMS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR AND THEIR IMPLICATIONS; TREATMENTS DIRECTED AT THE BASIC DEFECT; CLINICAL MANIFESTATIONS OF CYSTIC FIBROSIS; OUTCOMES IN CYSTIC FIBROSIS: IMPROVEMENTS AND CHALLENGES; INCREASING ADULT POPULATION OF CYSTIC FIBROSIS PATIENTS CYSTIC FIBROSIS CENTERS: IMPACT ON OUTCOMESREFERENCES; Genetics of Cystic Fibrosis; Key points; INTRODUCTION; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN MUTATIONS AND THE DISEASE SPECTRUM; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN MUTATIONS DIVIDED INTO FUNCTIONAL CLASSES; MODIFIERS; GENETICS AND DIAGNOSIS; GENETICS AND THERAPIES; Gene Therapy: Replacement or Edit; SMALL MOLECULES DIRECTED AT FIXING MUTANT CFTR; APPROVED AGENTS: (IVACAFTOR AND IVACAFTOR/LUMACAFTOR); Ivacaftor; Individuals with the G551D CFTR mutation Individuals with non-G551D gating mutations and class IV mutationsIvacaftor and F508del Mutation; Safety of Ivacaftor; Lumacaftor Plus Ivacaftor: Challenges with Correcting F508del; ADVERSE EVENTS; EMERGING THERAPIES; EMERGING READ-THROUGH AGENTS: ATALUREN; SUMMARY; REFERENCES; Innate and Adaptive Immunity in Cystic Fibrosis; Key points; INNATE IMMUNITY; Altered Barrier Function Impairs Host Defense in Cystic Fibrosis; Reduced mucociliary clearance; Altered airway surface liquid composition; Airway surface liquid acidification; Increased protease activity; Oxidative environment
• Publisher Details: Philadelphia, PA : Elsevier
• Publication Date: 2016
• Extent: 1 online resource
• Subjects: 617.5407572; Cystic fibrosis -- Research; Cystic fibrosis -- Diagnosis; MEDICAL / Surgery / General; Cystic fibrosis -- Diagnosis; Cystic fibrosis -- Research; Electronic books
• Languages: English
• ISBNs: 9780323416429
• Related ISBNs: 032341642X; 9780323416412
• Notes: Note: Online resource; title from PDF title page (EBSCO, viewed June 6, 2016).
• Access Rights: Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK).
• Access Usage: Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force.